Recombinant Human Papillomavirus Type 6/11 Bivalent Vaccine (Hansenula polymorpha, Jiangsu Recbio Technology)

重组人乳头瘤病毒6/11型二价疫苗 (汉逊酵母，江苏瑞科生物)

Report date: 2025/12/11 09:50:57

Base Information

Drug NameRecombinant Human Papillomavirus Type 6/11 Bivalent Vaccine (Hansenula polymorpha, Jiangsu Recbio Technology)
Drug Alias NameHPV Bivalent (Type 6/11) Vaccine (jiangsu ruike biotechnology)重组二价（16，11）HPV疫苗（铝佐剂）HPV-6/11 vaccine (jiangsu ruike biotechnology)Recombinant HPV bivalent (Types 6/11) vaccine (Alum)REC602 +[6] 
ClassificationVaccines > Biological material > Viral vaccineVaccines > Vaccine type > Multivalent vaccineVaccines > Application > Prophylactic vaccine +[4] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsPapillomavirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiangsu Rec-Biotechnology Co LtdAbzymo Biosciences Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAbzymo Biosciences Co LtdJiangsu Rec-Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsPapillomavirus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A